Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the PEG ratio high or low?
The PEG ratio of 2.17 is 13% below its 1-year average of 2.50, near the low end of its 1-year range (1.99–3.05).
As of 2026-10-06T22:13:56.979Z.
Calculation as of: 2026-10-06T22:13:56.979Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 74406e0af2a3ae2a0a3321f422a2c0552e1ec64c3f78dd1595dbf6a414c23681
PEG RATIO
2.17
PEG RATIO AVG TTM
N/A
PEG RATIO AVG 3Y
N/A
PEG RATIO AVG 5Y
N/A
PEG RATIO AVG 10Y
N/A
PEG RATIO AVG 15Y
N/A
PEG RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
1.92
median of 66 covered companies
CURRENT VS SECTOR MEDIAN
+12.73%
vs the sector median at left
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vericel Corporation (VCEL) | $2.05B | 2.17 | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | N/A | N/A | N/A |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | N/A | N/A | N/A | N/A |
| Progyny, Inc. (PGNY)vs › | $2.03B | 4.20 | 4.69 | 1.94 | 1.94 |
| Alvotech (ALVO)vs › | $2.08B | N/A | N/A | N/A | N/A |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | N/A | N/A | N/A | N/A |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | N/A | N/A | N/A | N/A |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | N/A | N/A | N/A | N/A |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | N/A | N/A | N/A | N/A |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | N/A | N/A | N/A | N/A |
PEG Ratio
2.17
P/E Ratio
85.6
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PEG RATIO |
|---|---|
| 2026-10-05 | 2.22 |
| 2026-10-02 | 2.17 |
| 2026-10-01 | 2.13 |
| 2026-09-30 | 2.17 |
| 2026-09-29 | 2.20 |
| 2026-09-28 | 2.18 |
| 2026-09-25 | 2.15 |
| 2026-09-24 | 2.13 |
| 2026-09-23 | 2.10 |
| 2026-09-22 | 2.18 |
| 2026-09-21 | 2.14 |
| 2026-09-18 | 2.17 |
| 2026-09-17 | 2.17 |
| 2026-09-16 | 2.18 |
| 2026-09-15 | 2.15 |
| 2026-09-14 | 2.14 |
| 2026-09-11 | 2.08 |
| 2026-09-10 | 2.05 |
| 2026-09-09 | 2.11 |
| 2026-09-08 | 2.12 |
| 2026-09-04 | 2.18 |
| 2026-09-03 | 2.19 |
| 2026-09-02 | 2.21 |
| 2026-09-01 | 2.19 |
| 2026-08-31 | 2.16 |
| 2026-08-28 | 2.22 |
| 2026-08-27 | 2.23 |
| 2026-08-26 | 2.30 |
| 2026-08-25 | 2.34 |
| 2026-08-24 | 2.29 |
| 2026-08-21 | 2.31 |
| 2026-08-20 | 2.28 |
| 2026-08-19 | 2.36 |
| 2026-08-18 | 2.40 |
| 2026-08-17 | 2.36 |
| 2026-08-14 | 2.39 |
| 2026-08-13 | 2.41 |
| 2026-08-12 | 2.42 |
| 2026-08-11 | 2.40 |
| 2026-08-10 | 2.38 |
| 2026-08-07 | 2.44 |
| 2026-08-06 | 2.42 |
| 2026-08-05 | 2.46 |
| 2026-08-04 | 2.51 |
| 2026-08-03 | 2.49 |
| 2026-07-31 | 2.49 |
| 2026-07-30 | 2.89 |
| 2026-07-29 | 2.83 |
| 2026-07-28 | 2.84 |
| 2026-07-27 | 2.75 |
| 2026-07-24 | 2.74 |
| 2026-07-23 | 2.74 |
| 2026-07-22 | 2.71 |
| 2026-07-21 | 2.80 |
| 2026-07-20 | 2.79 |
| 2026-07-17 | 2.83 |
| 2026-07-16 | 2.90 |
| 2026-07-15 | 2.84 |
| 2026-07-14 | 2.80 |
| 2026-07-13 | 2.89 |
| 2026-07-10 | 2.86 |
| 2026-07-09 | 2.94 |
| 2026-07-08 | 2.86 |
| 2026-07-07 | 2.85 |
| 2026-07-06 | 2.83 |
| 2026-07-02 | 2.85 |
| 2026-07-01 | 2.74 |
| 2026-06-30 | 2.70 |
| 2026-06-29 | 2.74 |
| 2026-06-26 | 2.81 |
| 2026-06-25 | 2.61 |
| 2026-06-24 | 2.53 |
| 2026-06-23 | 2.45 |
| 2026-06-22 | 2.46 |
| 2026-06-18 | 2.44 |
| 2026-06-17 | 2.38 |
| 2026-06-16 | 2.34 |
| 2026-06-15 | 2.33 |
| 2026-06-12 | 2.28 |
| 2026-06-11 | 2.34 |
| 2026-06-10 | 2.27 |
| 2026-06-09 | 2.25 |
| 2026-06-08 | 2.17 |
| 2026-06-05 | 2.21 |
| 2026-06-04 | 2.17 |
| 2026-06-03 | 2.11 |
| 2026-06-02 | 2.09 |
| 2026-06-01 | 1.99 |
| 2026-05-29 | 2.02 |
| 2026-05-28 | 2.08 |
| 2026-05-27 | 2.08 |
| 2026-05-26 | 2.12 |
| 2026-05-22 | 2.11 |
| 2026-05-21 | 2.14 |
| 2026-05-20 | 2.15 |
| 2026-05-19 | 2.10 |
| 2026-05-18 | 2.12 |
| 2026-05-15 | 2.01 |
| 2026-05-14 | 2.01 |
| 2026-05-13 | 2.00 |
| 2026-05-12 | 2.00 |
| 2026-05-11 | 2.00 |
| 2026-05-08 | 2.03 |
| 2026-05-07 | 2.90 |
| 2026-05-06 | 3.04 |
| 2026-05-05 | 3.04 |
| 2026-05-04 | 3.01 |
| 2026-05-01 | 2.94 |
| 2026-04-30 | 2.87 |
| 2026-04-29 | 2.76 |
| 2026-04-28 | 2.94 |
| 2026-04-27 | 3.05 |
| 2026-04-24 | 2.94 |
| 2026-04-23 | 2.84 |
| 2026-04-22 | 2.84 |
| 2026-04-21 | 2.78 |
| 2026-04-20 | 2.96 |
| 2026-04-17 | 2.94 |
| 2026-04-16 | 2.79 |
| 2026-04-15 | 2.92 |
| 2026-04-14 | 2.90 |
| 2026-04-13 | 2.84 |
| 2026-04-10 | 2.78 |
| 2026-04-09 | 2.77 |
| 2026-04-08 | 2.81 |
| 2026-04-07 | 2.75 |
| 2026-04-06 | 2.81 |
| 2026-04-02 | 2.82 |
| 2026-04-01 | 2.69 |
| 2026-03-31 | 2.66 |
| 2026-03-30 | 2.52 |
| 2026-03-27 | 2.42 |
| 2026-03-26 | 2.54 |
| 2026-03-25 | 2.60 |
| 2026-03-24 | 2.73 |
| 2026-03-23 | 2.68 |
| 2026-03-20 | 2.59 |
| 2026-03-19 | 2.70 |
| 2026-03-18 | 2.67 |
| 2026-03-17 | 2.68 |
| 2026-03-16 | 2.67 |
| 2026-03-13 | 2.68 |
| 2026-03-12 | 2.65 |
| 2026-03-11 | 2.71 |
| 2026-03-10 | 2.76 |
| 2026-03-09 | 2.82 |
| 2026-03-06 | 2.78 |
| 2026-03-05 | 2.81 |
| 2026-03-04 | 2.89 |
| 2026-03-03 | 2.84 |
| 2026-03-02 | 2.92 |
| 2026-02-27 | 2.94 |